This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Orphan designation: Magrolimab Treatment of myelodysplastic syndromes, 26/06/202...
Orphan designation: autologous T cells transduced with lentiviral vector contain...
Orphan designation: Ornithine phenylacetate Treatment of acute liver failure, 20...
Orphan designation: Serplulimab Treatment of small cell lung cancer, 20/02/2025 ...
Orphan designation: Adeno-associated viral vector serotype rh10 containing the h...
Orphan designation: pelabresib monohydrate Treatment of myelofibrosis, 17/02/202...
Orphan designation: Upifitamab rilsodotin Treatment of ovarian cancer, 09/12/202...
Orphan designation: sutimlimab Treatment of autoimmune haemolytic anaemia, 11/02...
IRIS guide for applicants - How to create and submit scientific applications, fo...
Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,...
Herbal medicinal product: Urticae radix, Urtica dioica L.,Urtica urens L., F: As...
Human medicines European public assessment report (EPAR): Yselty, linzagolix cho...
Human medicines European public assessment report (EPAR): Sugammadex Mylan, suga...
Human medicines European public assessment report (EPAR): Rekambys, rilpivirine,...
Human medicines European public assessment report (EPAR): Gencebok, caffeine cit...
Human medicines European public assessment report (EPAR): Sarclisa, isatuximab, ...
Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, ...
Summary of the Medicine Shortages SPOC Working Party meeting on 21 January 2025
Human medicines European public assessment report (EPAR): Wainzua, eplontersen, ...
CTIS newsflash - 11 March 2025
SPOR and XEVMPD status update webinar, Broadcast, from 9 July 2025, 10:00 (CEST)...
Final European Union herbal monograph on Urtica dioica L.; Urtica urens L., radi...
Final list of references supporting the assessment of Urtica dioica L.; Urtica u...